powerpadman
Member
- Joined
- Nov 30, 2023
- Messages
- 25
- Reason
- Loved one DX
- Diagnosis
- 11/2023
- Country
- US
- State
- WA
Here's a white paper written in just 2022.
Dutasteride is a medication that treats benign prostatic hyperplasia and symptoms of an enlarged prostate. It's often used off label for hair loss. Could there be a link between DHT and ALS?
Summary of the white paper:
Dutasteride is a possible candidate for the treatment of ALS. This molecule shows neuroprotective effects against glutamate toxicity in animal models, which opens new paths due to the direct implication of the neurotransmitter excitability in ALS. In addition, it also shows anti-inflammatory activity, as it has been observed that it reduces the secretion of both IL-6 and TNFα in vitro and decreases the activation of microglia in the brain. Reducing the TNFα increase could counteract the inflammation and oxidation levels caused by abnormal protein aggregates, which, together with its ability to inhibit the Keap1–Nrf2 interaction, would complete its anti-inflammatory activity. In turn, steroid hormones, increased by the inhibition of the 5AR activity due to dutasteride, are shown to be powerful anti-inflammatory and antioxidant agents, and they are capable of stabilizing the BBB and reducing the excitotoxicity caused by excess glutamate. T, PROG and 17BE can also inhibit microglial activation, thus playing a neuroprotective role, and especially in relation to the altered DA activity in the disease. Regarding the mutations and protein aggregates identified in ALS, the increase in T could also counteract the formation of aggregates of FUS, VCP and TDP-43, which, in turn, are linked to C9ORF72 mutations. All of these processes are directly related to the pathogenesis of ALS, which is why hormone therapy seems to be a good alternative against it.
The activity of dutasteride and its hormonal products could clinically improve ALS. On the basis of the extensive muscle deterioration and atrophy in this type of patient, androgen therapies restore the neuromuscular-junction function and increase the muscle mass, which improve the functional capacity and quality of life. Because there are few studies in this field, the possible benefits of dutasteride administration as a therapeutic alternative for ALS should be studied in depth, and especially its impact on the steroid-hormone levels in serum and CSF, and its relationship with protein aggregates.
Dutasteride is a medication that treats benign prostatic hyperplasia and symptoms of an enlarged prostate. It's often used off label for hair loss. Could there be a link between DHT and ALS?
Summary of the white paper:
Dutasteride is a possible candidate for the treatment of ALS. This molecule shows neuroprotective effects against glutamate toxicity in animal models, which opens new paths due to the direct implication of the neurotransmitter excitability in ALS. In addition, it also shows anti-inflammatory activity, as it has been observed that it reduces the secretion of both IL-6 and TNFα in vitro and decreases the activation of microglia in the brain. Reducing the TNFα increase could counteract the inflammation and oxidation levels caused by abnormal protein aggregates, which, together with its ability to inhibit the Keap1–Nrf2 interaction, would complete its anti-inflammatory activity. In turn, steroid hormones, increased by the inhibition of the 5AR activity due to dutasteride, are shown to be powerful anti-inflammatory and antioxidant agents, and they are capable of stabilizing the BBB and reducing the excitotoxicity caused by excess glutamate. T, PROG and 17BE can also inhibit microglial activation, thus playing a neuroprotective role, and especially in relation to the altered DA activity in the disease. Regarding the mutations and protein aggregates identified in ALS, the increase in T could also counteract the formation of aggregates of FUS, VCP and TDP-43, which, in turn, are linked to C9ORF72 mutations. All of these processes are directly related to the pathogenesis of ALS, which is why hormone therapy seems to be a good alternative against it.
The activity of dutasteride and its hormonal products could clinically improve ALS. On the basis of the extensive muscle deterioration and atrophy in this type of patient, androgen therapies restore the neuromuscular-junction function and increase the muscle mass, which improve the functional capacity and quality of life. Because there are few studies in this field, the possible benefits of dutasteride administration as a therapeutic alternative for ALS should be studied in depth, and especially its impact on the steroid-hormone levels in serum and CSF, and its relationship with protein aggregates.
